Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Glycerol Phenylbutyrate→

Glycerol Phenylbutyrate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
611168-24-2
Molecular formula
C33H38O6
Molecular weight
530.6 g/mol
Drug class
Nitrogen-scavenging prodrugglycerol ester of phenylbutyrate
Mechanism of action
Hydrolysed to phenylbutyrate, which is oxidised to phenylacetate. Phenylacetate conjugates with glutamine to form phenylacetylglutamine, which is excreted in urine and provides an alternative pathway for nitrogen waste elimination in urea-cycle disorders.
Indications / reported uses
  • Chronic management of patients with urea-cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino-acid supplementation alone; not for treatment of acute hyperammonaemia

Sources: US DailyMed — RAVICTI (glycerol phenylbutyrate) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Glycerol Phenylbutyrate Environmental Risk Assessment (ERA) (the Glycerol Phenylbutyrate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.